Host the 2025 Clinical Endocrinology Journal Foundation Visiting Professor

Professor Martin Fassnacht will be joining our plenary lecturers at SfE BES 2025 and you are invited to host him during the week prior to the conference.

He will be touring up to five endocrine centres in the UK during the week commencing Monday 3 March. If you or colleagues would like to be considered to host a visit, please email us at [email protected] by 21 June 2024.

The programme for the day visit is entirely up to you and may, if travel schedule allows, involve an evening dinner. All costs for the visit except travel and accommodation are borne by the host institution.

About Professor Martin Fassnacht
Martin Fassnacht is Professor of Internal Medicine and Endocrinology and Chair of the Department of Endocrinology and Diabetes at the University Hospital in Würzburg, Germany. He studied medicine at the School of Medicine at the Universities of Saarbrücken and Würzburg and completed his medical training in Würzburg. In-between he joined the Duke University in North Carolina as postdoctoral fellow for 2 years. In 2012, he was appointed Professor of Endocrinology at the University of Munich and since 2014 he is the successor of Bruno Allolio in Würzburg.

Martin served on several boards of national and international endocrine societies including the Publication Core Committee of the Endocrine Society (2012-18) Clinical Committee of ESE (2013-17), ExCo of the German Society of Endocrinology (2014-17), and since 2021 the ESE ExCo. He has been a founding member, working group head and from 2016-2021 president of the European Network for the Study of Adrenal Tumors (ENSAT).

His main scientific interests are endocrine tumors, adrenal and pituitary diseases, and obesity. Martin heads a large translational research group, was principal investigator of several phase II and III trials in adrenal tumors, and has authored more than 300 publications.

He has organized numerous scientific meetings and has chaired several national and international guideline panels (e.g. ESE-ENSAT guidelines on adrenal incidentaloma 2016+ 2023, ESE-ENSAT guidelines on adrenocortical carcinoma 2018, German guideline on pituitary tumors 2020, ESMO guidelines on adrenocortical carcinoma and malignant pheochromocytoma 2020).